DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Zonisamide as add-on treatment for focal epilepsies. An outcome analysis of 74 patients]

Author(s): Wellmer S, Wellmer J, Bauer J

Affiliation(s): Klinik fur Epileptologie, Universitatsklinikum Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn.

Publication date & source: 2008-12, Nervenarzt., 79(12):1416, 1418-23.

Publication type: English Abstract

BACKGROUND: Evaluation of efficacy and tolerability of zonisamide (ZNS) used as an add-on treatment in patients with chronic focal epilepsies. MATERIAL AND METHODS: Retrospective data analysis in 74 patients (38 men, 36 women), age 17-61 years (mean 35 years). Duration of epilepsy was 2-50 years (mean 23.3 years). Additional antiepileptic drugs 2-5 (mean 2.7). RESULTS: The ZNS daily dosage varied between 100 mg and 500 mg (mean 368 mg). Seizure frequency could be estimated in 50 patients; it decreased by at least 50% in 11 patients (22%), remained unchanged in 28 patients (56%), and increased by at least 50% in 11 patients (22%). None of the patients achieved complete seizure control. Side effects were seen in 45/74 patients (60.8%). Adverse events resulting in discontinuation of treatment with ZNS were documented in 24 patients (32.4%). Out of 70 patients, 34 (48.5%) remained on ZNS 12 months after the onset of therapy. CONCLUSIONS: In this study, ZNS proved to be an antiepileptic drug with a comparatively low anticonvulsant efficacy as an add-on treatment in patients with chronic focal epilepsies.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017